Cardiff Oncology, Inc. current report, 01 June 2007

SEC Filing Summary: Xenomics, Inc. (Form 8-K)

Business Context and Reporting Period

This Form 8-K was filed by Xenomics, Inc. on June 4, 2007, reporting events occurring on June 1, 2007. The registrant is incorporated in Florida with principal executive offices in New York, New York. Note: The request metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.

Material Changes

Under Item 5.02, the company reported the voluntary resignation of Frederick Larcombe as Chief Financial Officer. The resignation is effective July 31, 2007.

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the officer departure.

Key Facts for Investor Verification

  • Frederick Larcombe resigned as CFO effective July 31, 2007.
  • The resignation was voluntary.
  • The filing does not disclose a successor CFO or interim financial leadership arrangements.
  • Verify if this departure impacts ongoing financial reporting or audit processes.